OPPS/ASC CY2027 Proposed Rule: Botulinum Toxin Prior Authorization Expansion
FR-2026-13656 proposes expanding Medicare prior authorization requirements for Botulinum Toxin under the CY2027 OPPS/ASC payment system.
The CY2027 Hospital Outpatient Prospective Payment System and Ambulatory Surgical Center Payment Systems Proposed Rule (FR-2026-13656) proposes expanding prior authorization requirements for Botulinum Toxin services billed under OPPS and the ASC payment system. This is a Proposed Rule published in the Federal Register; it is not yet final, and the effective date is not determinable from the summary — see the source document at the URL below for comment deadlines and proposed implementation dates. The single most important compliance implication for outpatient facility coders and revenue cycle directors is this: if finalized, claims for Botulinum Toxin administered in hospital outpatient departments or ASCs will require an approved prior authorization before reimbursement is issued, mirroring the prior auth framework already in place for other non-emergency outpatient services.
Regulatory Background
Sign in to read the full article
Create a free account to access the complete analysis, action recommendations, and related alert references.
Quick answers
Does the proposed prior authorization requirement for Botulinum Toxin under FR-2026-13656 apply to both hospital outpatient department claims and ASC facility claims?
Yes — the proposed rule names both the OPPS and ASC payment systems as affected. This means the prior authorization requirement, if finalized, would apply to 837I institutional claims submitted by hospital outpatient departments and to ASC facility claims. Confirm the specific HCPCS J-codes covered by reviewing the full Federal Register text of FR-2026-13656.
Since FR-2026-13656 is a Proposed Rule, do we need to change our Botulinum Toxin billing workflow now?
No immediate claim-level change is required — the prior authorization requirement is not yet final. However, revenue cycle directors should use the proposed rule comment and finalization window to design the prior authorization workflow, update CDM flags, and confirm 837I loop/segment mapping for prior auth numbers, so that implementation is not rushed if CMS finalizes the rule on a standard CY2027 timeline. Verify the comment period deadline in the full Federal Register document.
Where in the 837I claim is the prior authorization number submitted for OPPS prior auth requirements?
The source summary does not specify the exact loop and segment. Under the existing OPPS prior authorization framework for other service categories, the prior auth reference number is generally carried in the 837I transaction. Confirm the precise field mapping with your clearinghouse or billing system vendor and test that configuration before any compliance date identified in the finalized rule.
Content summarized from publicly available federal publications including CMS, MAC contractors, and the Federal Register. CLV Intelligence is not affiliated with or endorsed by any government agency. This is not legal or medical advice.